Vitiligo is clinically characterized by the appearance of non-symptomatic depigmented macules, but the disorder is highly correlated with a wide range of psychiatric disorders and psychological problems. The aim of our study was to investigate serum brain-derived neurotrophic factor (BDNF) and corticotropin releasing hormone (CRH) levels in vitiligo patients and healthy controls in relation to the observed symptoms of depression and anxiety disorders. This study comprised 96 vitiligo patients and 96 healthy controls who filled out the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) scales. Serum levels of BDNF and CRH were measured using enzyme-linked immunosorbent assay (ELISA) technique. There was a significant increase of depression and anxiety scores in vitiligo patients as compared with healthy controls (P < 0.05). The serum levels of BDNF were significantly lower in vitiligo patients than in healthy individuals (Z = 4.002; P < 0.001), while the serum levels of CRH were markedly higher in cases than those in controls (Z = 3.764; P < 0.001). The significant positive correlations between serum CRH levels and GAD-7, PHQ-9 scores were observed. However, the aforementioned psychometric scales did not correlate significantly with serum BDNF level. Vitiligo is associated with the depression and is closely linked with lower BDNF levels.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068776 | PMC |
http://dx.doi.org/10.1038/s41598-022-11028-8 | DOI Listing |
Clin Cosmet Investig Dermatol
December 2024
Department of Dermatology, Air Force Medical Center, PLA, Beijing, People's Republic of China.
Background: Vitiligo is a chronic autoimmune disease manifested by depigmented patches of skin devoid of melanocytes. Baricitinib, a JAK inhibitor selectively targeting JAK1/2, has shown preliminary efficacy for vitiligo. We aimed to assess the efficacy and tolerability of combination therapy with baricitinib and narrowband UV-B (NB-UVB) to treat active nonsegmental vitiligo (NSV).
View Article and Find Full Text PDFJ Family Med Prim Care
November 2024
Department of Dermatology, King Fahad Medical City (KFMC), Riyadh, Saudi Arabia.
Vitiligo, a prevalent cutaneous depigmentation disorder, often leads individuals to seek cosmetic remedies such as dihydroxyacetone (DHA)-infused camouflage makeup. Wood's lamp, a common diagnostic tool in dermatology, is typically employed to assess vitiligo lesions, revealing DHA-induced fluorescence in a distinct salmon color, contrasting with the bright blue-white fluorescence exhibited by vitiligo lesions. Erythrasma, a bacterial infection of the epidermis, is known for its unique bright coral-pink or coral-red fluorescence under Wood's lamp.
View Article and Find Full Text PDFBull Menninger Clin
December 2024
Emergency medicine physician, NYC Health + Hospitals, Department of Emergency Medicine.
This review focuses on chronic pediatric skin conditions-vitiligo, psoriasis, alopecia, and eczema-and their profound psychosocial impact on children and adolescents. Currently, a comprehensive comparative analysis across these conditions is absent, and comparisons between diverse psychosocial measures are lacking. This review aims to bridge that gap through a systematic review analyzing studies from PubMed and Embase up to April 2023 according to PRISMA.
View Article and Find Full Text PDFInt J Pharm
December 2024
Department of Pharmacology, Rungta College of Pharmaceutical Sciences and Research, Bhilai, Chhattisgarh 490024, India.
Vitiligo is a complex dermatological disorder involving the loss of melanocytes, with resultant patches of depigmentation. It affects 1% of the world population, affecting patients' mental health and quality of life. With all the improvement seen, conventional treatment methods-steroids, phototherapy, and immunomodulators-come with the limitations of being less effective, having more side effects, and low compliance.
View Article and Find Full Text PDFJAMA Dermatol
December 2024
Oncodermatology Department, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!